LAVA Therapeutics to Present Corporate Overview at 40th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

LAVA Therapeutics N.V. (Nasdaq: LVTX) has announced that CEO Stephen Hurly will present a corporate overview at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2021, at 1:30 p.m. EST. The company is focused on its Gammabody™ platform, which develops bispecific gamma delta T cell engagers for cancer treatment. Hurly expressed optimism about the company’s transformative journey in 2021 and its patient recruitment for Gammabody™ programs. Data from ongoing clinical studies is expected in 2022, with active recruitment for prostate cancer trials.

UTRECHT, The Netherlands and PHILADELPHIA, Dec. 20, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers (bsTCEs) to transform the treatment of cancer, today announced that Stephen Hurly, chief executive officer, will present a corporate overview at the 40^th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 12, 2021 at 1:30 p.m. EST.

“We are excited to round out a transformative 2021 and eager to kick-off what promises to be an exciting 2022 for LAVA,” said Stephen Hurly, president and chief executive officer. “With both of our lead liquid and solid tumor Gammabody™ programs actively recruiting patients, our focus is on carrying out our mission to rapidly develop new cancer treatments that leverage gamma delta T cells to save patients’ lives.”

Access to the recording will be available under the "Events" tab on the investor relations section of the LAVA Therapeutics website at: https://ir.lavatherapeutics.com/news-events/events.

About LAVA Therapeutics
LAVA Therapeutics N.V. is a clinical-stage biotechnology company utilizing its proprietary Gammabody™ platform to develop a portfolio of bispecific gamma delta T cell engagers (gamma delta bsTCEs) for the potential treatment of solid tumors and hematological malignancies. The company’s innovative approach utilizes bispecific antibodies engineered to selectively kill cancer cells via the triggering of Vγ9Vδ2 T cell antitumor effector functions upon cross-linking to tumor associated antigens. A Phase 1/2a clinical study evaluating LAVA-051 in patients with certain hematological malignancies is currently enrolling (NCT04887259). The company currently anticipates data from the Phase 1 dose escalation phase of the study in the first half of 2022 with top line clinical data from the Phase 2a expansion cohorts expected in the second half of 2022. The company is actively recruiting patients in a Phase 1/2a clinical study to evaluate LAVA-1207 in patients with prostate cancer. For more information, please visit www.lavatherapeutics.com and follow us on LinkedIn and Twitter.

LAVA’s Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, including in respect of the company’s anticipated growth and clinical developments plans, including the timing of clinical trials. Words such as “anticipate,” “believe,” “could,” “will,” “may,” “expect,” “should,” “plan,” “intend,” “estimate,” “potential” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on LAVA’s expectations and assumptions as of the date of this press release and are subject to various risks and uncertainties that may cause actual results to differ materially from these forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the preclinical data, clinical development and scope of clinical trials, and the potential use of our product candidates to treat various tumor targets. Many factors, risks and uncertainties may cause differences between current expectations and actual results including, among other things, the timing and results of our research and development programs and preclinical and clinical trials, our ability to obtain regulatory approval for and commercialize our product candidates, our ability to leverage our initial programs to develop additional product candidates using our Gammabody™ platform, and the failure of LAVA’s collaborators to support or advance collaborations or our product candidates. In addition, the COVID-19 pandemic may disrupt our business and that of the third parties on which we depend, including delaying or otherwise disrupting our clinical trials and preclinical studies, manufacturing and supply chain, or impairing employee productivity. LAVA assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

CONTACT
Edward Smith
Chief Financial Officer
ir@lavatherapeutics.com 

Catherine Day
+1-917-763-2709
catherine@newdaybioconsulting.com

FAQ

When will LAVA Therapeutics present at the J.P. Morgan Healthcare Conference?

LAVA Therapeutics will present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2021, at 1:30 p.m. EST.

What is the focus of LAVA Therapeutics and its Gammabody™ platform?

LAVA Therapeutics focuses on developing bispecific gamma delta T cell engagers for cancer treatment through its proprietary Gammabody™ platform.

What updates did LAVA Therapeutics provide about clinical studies?

LAVA is actively recruiting patients for its Gammabody™ programs and expects data from ongoing clinical studies in the first half of 2022.

What types of tumors is LAVA Therapeutics targeting?

LAVA Therapeutics is targeting both solid tumors and hematological malignancies with its gamma delta T cell engagers.

Where can I find more information about LAVA Therapeutics?

More information about LAVA Therapeutics can be found on their official website at www.lavatherapeutics.com.